Why does only free drug matter if most of a drug is protein-bound?

Protein-bound drug cannot cross membranes or bind its target; only the unbound fraction distributes, acts, and is eliminated, so the free concentration determines pharmacological effect even when most of the drug is bound.

Are protein-binding drug interactions usually clinically important?

For most drugs, no: when one drug displaces another from binding, the transient rise in free drug is offset by increased clearance and redistribution, so steady-state free exposure changes little; clinically relevant exceptions are limited to some highly bound, narrow-therapeutic-index drugs.

Protein Binding

Many drugs circulate in blood partly bound to plasma proteins, chiefly albumin (which binds acidic and neutral drugs) and alpha-1-acid glycoprotein (which binds many basic drugs). Because only the unbound, or free, drug can cross membranes, engage targets, and be cleared, the equilibrium between bound and free drug is a central determinant of drug distribution and effect.

Definition

Protein binding is the reversible, usually non-covalent association of a drug with plasma or tissue proteins, establishing an equilibrium between bound and unbound (free) drug in which only the free fraction is pharmacologically active and available for distribution and elimination.

Scope

This topic covers the reversible binding of drugs to plasma (and tissue) proteins: the principal binding proteins, the concept of the unbound fraction, how binding shapes distribution and the interpretation of total drug concentrations, and the much-debated clinical importance of changes in protein binding. It is a reference and educational entry within pharmacokinetics and offers no dosing guidance.

Core questions

Which plasma proteins bind drugs, and how does binding depend on drug chemistry?
Why does only the unbound (free) fraction of a drug determine its distribution and effect?
How does protein binding affect the interpretation of measured total drug concentrations?
Under what circumstances, if any, do changes in protein binding have clinical consequences?

Key concepts

Albumin and alpha-1-acid glycoprotein
Bound versus free (unbound) drug
Fraction unbound
Reversible binding equilibrium
Displacement interactions
Restrictive versus non-restrictive clearance
Total versus free drug concentration

Mechanisms

Drugs associate reversibly with binding sites on plasma proteins; albumin is the main carrier for acidic and neutral drugs, while alpha-1-acid glycoprotein binds many basic and lipophilic drugs. The equilibrium between bound and free drug is described by the fraction unbound, and because protein-bound drug cannot diffuse across membranes, only the free fraction distributes into tissues, acts on targets, and is presented to clearing organs. When two drugs compete for the same binding site, one may displace the other and transiently raise the free fraction; however, for most drugs a rise in free drug is offset by increased clearance and redistribution, so steady-state free concentrations and effect change less than the change in binding alone would suggest.

Clinical relevance

Protein binding is important for interpreting therapeutic drug monitoring, since most assays report total (bound plus free) concentrations even though only free drug is active; this matters most for highly bound drugs in states of altered protein levels. As a descriptive reference concept it supports evidence appraisal and is not a basis for individual dosing decisions.

Evidence & guidelines

The framework for protein binding is established in pharmacokinetic texts and reviews; the prevailing position in the literature is that, for most drugs, isolated changes in plasma protein binding have limited clinical impact because of compensating pharmacokinetic adjustments.

History

Recognition that drugs circulate partly bound to plasma proteins, and that displacement could alter free-drug exposure, led in the mid-twentieth century to concern about binding-based drug interactions. Later quantitative analyses, notably arguments that compensating changes in clearance buffer free-drug exposure, reframed many such interactions as clinically minor, refining the way protein binding is interpreted.

Debates

Do changes in plasma protein binding have clinically meaningful effects?: Displacement from binding sites was long thought to cause important drug interactions, but later analyses argued that for most drugs the free concentration at steady state is governed by clearance and dose rather than by binding, so binding changes are usually of limited clinical relevance; exceptions exist for some highly bound, narrow-index drugs.

Key figures

Leslie Benet
Jason Roberts
Malcolm Rowland

Seminal works

benet-2002
roberts-2013
lombardo-2002

Frequently asked questions

Why does only free drug matter if most of a drug is protein-bound?: Protein-bound drug cannot cross membranes or bind its target; only the unbound fraction distributes, acts, and is eliminated, so the free concentration determines pharmacological effect even when most of the drug is bound.
Are protein-binding drug interactions usually clinically important?: For most drugs, no: when one drug displaces another from binding, the transient rise in free drug is offset by increased clearance and redistribution, so steady-state free exposure changes little; clinically relevant exceptions are limited to some highly bound, narrow-therapeutic-index drugs.